Achilles Therapeutics has torn up its strategy. The British biotech is stopping work on its clinical-phase cell therapy, looking into deals with groups working on other modalities and preparing to lay off staff. Achilles has decided to stop development of its TIL-based therapy and close two phase 1/2a trials. CEO Iraj Ali, Ph.D., said the “studies in lung cancer and melanoma have not met our goals for commercial viability.” Source: Fierce Biotech 19/9/2024